58. Kurth T., MohamedS., Maillard P. et al. Headache, migraine, and structural brain lesions and function: population based Epidemiology of Vascular Ageing-MRI study. BMJ 2011; 342: 7357.
59. Kruit M.C., van Buchem M.A., Hofman P.A. et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004; 291: 4: 427--434.
60. Lipton R.B. Chronic migraine epidemiology, classification, and differential diagnosis. Presented at: Decoding chronic migraine: translating clinical trial data into optimal outcomes with novel therapies June 25, 2010; Los Angeles CA.
61. Lipton R.B. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009; 72: 3--7.
62. Lipton R.B., Varon S.F, Grosberg B., McAllister P.J., Freitag F., Aurora S.K., Dodick D.W, Silberstein S.D., Diener H.C., DeGryse R.E., Nolan M.E., Turkel C.C. Onabotulinumtoxin A improves quality of life and reduces impact of chronic migraine. Neurology 2011; 77: 15: 1465--1472.
63. Manack A., Buse D.C., Serrano D. et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76: 711--718.
64. Mathew N.T. Dynamic optimization of chronic migraine treatment: current and future options. Neurology 2009; 72: 5 Suppl: 14--20.
65. Mathew N.T. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache 2011; 51: 2: 84--92.
66. Munakata J., Hazard E., Serrano D. et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2009; 49: 498--508.
67. Natoli J.L., Manack A., Dean B. et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 30: 599--609.
68. Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 11: 1403--1406.
69. Reed M.L., Buse D.C., Manack A.N. et al. Prevalence of chronic migraine (CM), headache-related disability and sociodemographic factors in the US population: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2011; 51: 28.
70. Silberstein S.D., BlumenfeldA.M., Cady R.K., Turner I.M., Lipton R.B., Diener H.C., Aurora S.K., Sirimanne M., DeGryse R.E., Turkel C.C., Dodick D.W. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 15: 331: 1--2: 48--56.
71. Silberstein S.D., Edvinsson L. Is CGRP a marker for chronic migraine? Neurology 2013.
72. Silberstein S., Lipton R., Dodick D., Freitag F, Mathew N., Brandes J., Bigal M., Ascher S., Morein J., Wright P., Greenberg S., Hulihan J. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009; 49: 8: 1153--1162.
73. Silberstein S.D., Lipton R.B., Dodick D.W., Freitag F.G., Ramadan N., Mathew N., Brandes J.L., Bigal M., Saper J., Ascher S., Jordan D.M., Greenberg S.J., Hulihan J. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 2: 170-- 180.
74. Silberstein S.D., Lipton R.B., Saper J.R. Chronic daily headache including transformed migraine, chronic tension-type headache and medication overuse headache. In: S.D. Silberstein, R.B. Lipton, D.W. Dodick (eds) Wolff's headache and other head pain. Oxford University Press, New York 2008; 315--377.
75. Silberstein S., Tfelt-Hansen P., Dodick D.W., Limmroth V., Lipton R.B., Pas- cual J., Wang S.J. Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008; 28: 5: 484--495.
76. Schoenen J., Aliena M., Magis D. Neurostimulation therapy in intractable headaches. Handb Clin Neurol 2010; 97: 443--450.
77. Stewart W., Bruce C., Manack A. et al. A case study for calculating employer costs for lost productive time in episodic migraine and chronic migraine: results of the American Migraine Prevalence and Prevention Study. J Occup Environ Med 2011; 53: 10: 1161 -- 1171.
78. Stokes M., Becker W.J., Lipton R.B. et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache 2011; 51: 1058--1077.
79. Stovner L., Hagen K., Jensen R. et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27: 3: 193--210.
80. Teepker M., Hotzel J., Timmesfeld N. et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia 2010; 30: 2: 137--144.
81. Tronnier V., Rasche D. Subcutaneous peripheral stimulation of the greater occipital nerve for the treatment of chronic headache syndromes. Schmerz 2010; 24: 5: 441--448.
82. Valfre W., Rainero I., Bergui M., Pinessi L. Voxel-based morphometry reveals gray matter abnormalities in migraine. Headache 2008; 48: 1: 109-- 117.
83. Welch M.J., Purkiss J.R., Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 2: 245--258.